{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:15:23Z","timestamp":1775711723088,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00228-023-03549-6","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T08:02:38Z","timestamp":1692432158000},"page":"1401-1415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population pharmacokinetics of topiramate in Chinese children with epilepsy"],"prefix":"10.1007","volume":"79","author":[{"given":"Shifeng","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"issue":"13","key":"3549_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM (2022) Antiseizure medications for adults with epilepsy: a review. JAMA 327(13):1269\u20131281","journal-title":"JAMA"},{"issue":"15","key":"3549_CR2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","volume":"67","author":"KA Lyseng-Williamson","year":"2007","unstructured":"Lyseng-Williamson KA, Yang LP (2007) Topiramate: a review of its use in the treatment of epilepsy. Drugs 67(15):2231\u20132256","journal-title":"Drugs"},{"issue":"1","key":"3549_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","volume":"113","author":"H Stefan","year":"2007","unstructured":"Stefan H, Feuerstein TJ (2007) Novel anticonvulsant drugs. Pharmacol Ther 113(1):165\u2013183","journal-title":"Pharmacol Ther"},{"issue":"3\u20134","key":"3549_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ejps.2013.07.008","volume":"50","author":"M Jovanovi\u0107","year":"2013","unstructured":"Jovanovi\u0107 M, Soki\u0107 D, Grabnar I, Vovk T, Prostran M, Vu\u010di\u0107evi\u0107 K et al (2013) Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. Eur J Pharm Sci 50(3\u20134):282\u2013289","journal-title":"Eur J Pharm Sci"},{"issue":"S1","key":"3549_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","volume":"41","author":"WR Garnett","year":"2000","unstructured":"Garnett WR (2000) Clinical pharmacology of topiramate: a review. Epilepsia 41(S1):61\u201365","journal-title":"Epilepsia"},{"issue":"3","key":"3549_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17425255.2020.1724956","volume":"16","author":"C Johannessen Landmark","year":"2020","unstructured":"Johannessen Landmark C, Johannessen SI, Patsalos PN (2020) Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol 16(3):227\u2013238","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"3549_CR7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00228-022-03390-3","volume":"78","author":"J Methaneethorn","year":"2022","unstructured":"Methaneethorn J, Charoenchokthavee W (2022) Simulations of topiramate dosage recommendations for poor compliance events. Eur J Clin Pharmacol 78(11):1843\u20131850","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"3549_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45(11):1061\u20131075","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"3549_CR9","first-page":"1239","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI et al (2008) Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies Epilepsia 49(7):1239\u20131276","journal-title":"ILAE Commission on Therapeutic Strategies Epilepsia"},{"key":"3549_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/DDDT.S154388","volume":"12","author":"A Reimers","year":"2018","unstructured":"Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen LC (2018) Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther 12:271\u2013280","journal-title":"Drug Des Devel Ther"},{"key":"3549_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.seizure.2016.02.002","volume":"37","author":"EK Bae","year":"2016","unstructured":"Bae EK, Lee J, Shin JW, Moon J, Lee KJ, Shin YW et al (2016) Factors influencing topiramate clearance in adult patients with epilepsy: a population pharmacokinetic analysis. Seizure 37:8\u201312","journal-title":"Seizure"},{"issue":"2\u20133","key":"3549_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.eplepsyres.2010.12.004","volume":"93","author":"M Bouillon-Pichault","year":"2011","unstructured":"Bouillon-Pichault M, Nabbout R, Chhun S, Rey E, Chiron C, Dulac O et al (2011) Topiramate pharmacokinetics in infants and young children: contribution of population analysis. Epilepsy Res 93(2\u20133):208\u2013211","journal-title":"Epilepsy Res"},{"key":"3549_CR13","doi-asserted-by":"crossref","unstructured":"Brittain ST, Wheless JW (2015) Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Epilepsy Behav 52:31\u201336","DOI":"10.1016\/j.yebeh.2015.08.029"},{"issue":"2","key":"3549_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/apa.14944","volume":"109","author":"MR Marques","year":"2020","unstructured":"Marques MR, Garcia-Robles A, Usach I, Vento M, Poveda JL, Peris JE et al (2020) Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule. Acta Paediatr 109(2):300\u2013308","journal-title":"Acta Paediatr"},{"issue":"2","key":"3549_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/FTD.0000000000000383","volume":"39","author":"M Takeuchi","year":"2017","unstructured":"Takeuchi M, Yano I, Ito S, Sugimoto M, Yamamoto S, Yonezawa A et al (2017) Population pharmacokinetics of topiramate in Japanese pediatric and adult patients with epilepsy using routinely monitored data. Ther Drug Monit 39(2):124\u2013131","journal-title":"Ther Drug Monit"},{"issue":"7","key":"3549_CR16","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1248\/bpb.33.1176","volume":"33","author":"T Vovk","year":"2010","unstructured":"Vovk T, Jakovljevi\u0107 MB, Kos MK, Jankovi\u0107 SM, Mrhar A, Grabnar I (2010) A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull 33(7):1176\u20131182","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"3549_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/bcp.12556","volume":"79","author":"GF Ahmed","year":"2015","unstructured":"Ahmed GF, Marino SE, Brundage RC, Pakhomov SV, Leppik IE, Cloyd JC et al (2015) Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. Br J Clin Pharmacol 79(5):820\u2013830","journal-title":"Br J Clin Pharmacol"},{"key":"3549_CR18","doi-asserted-by":"crossref","unstructured":"Langtry HD, Gillis JC, Davis Topiramate R (1997) A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54(5):752\u2013773","DOI":"10.2165\/00003495-199754050-00009"},{"issue":"5","key":"3549_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.eplepsyres.2014.03.011","volume":"108","author":"P Manitpisitkul","year":"2014","unstructured":"Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald DL (2014) Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment. Epilepsy Res 108(5):891\u2013901","journal-title":"Epilepsy Res"},{"issue":"4","key":"3549_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","volume":"34","author":"C Johannessen Landmark","year":"2012","unstructured":"Johannessen Landmark C, Baftiu A, Tysse I, Vals\u00f8 B, Larsson PG, Rytter E et al (2012) Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit 34(4):440\u2013445","journal-title":"Ther Drug Monit"},{"issue":"12","key":"3549_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamaneurol.2022.3651","volume":"79","author":"D McKnight","year":"2022","unstructured":"McKnight D, Morales A, Hatchell KE, Bristow SL, Bonkowsky JL, Perry MS et al (2022) Genetic testing to inform epilepsy treatment management from an international study of clinical practice. JAMA Neurol 79(12):1267\u20131276","journal-title":"JAMA Neurol"},{"issue":"2","key":"3549_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1037\/a0015700","volume":"17","author":"LA Ray","year":"2009","unstructured":"Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ et al (2009) A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 17(2):122\u2013129","journal-title":"Exp Clin Psychopharmacol"},{"issue":"3","key":"3549_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"3549_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115437","volume":"232","author":"R Jiang","year":"2023","unstructured":"Jiang R, Zhang D, Zhao Z, Mei S (2023) Simultaneous determination of 24 antiepileptic drugs and their active metabolites in human plasma by UHPLC-MS\/MS. J Pharm Biomed Anal 232:115437","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"3549_CR25","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1755-5949.2012.00321.x","volume":"18","author":"BT Zhou","year":"2012","unstructured":"Zhou BT, Zhou QH, Yin JY, Li GL, Qu J, Xu XJ et al (2012) Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci Ther 18(7):566\u2013572","journal-title":"CNS Neurosci Ther"},{"key":"3549_CR26","doi-asserted-by":"crossref","unstructured":"Zhang ML, Chen XL, Bai ZF, Zhao X, Li WX, Wang XY et al (2021) ABCB1 c.3435C\u00a0>\u00a0T and EPHX1 c.416A\u00a0>\u00a0G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients. Gene 805:145907","DOI":"10.1016\/j.gene.2021.145907"},{"issue":"3","key":"3549_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/ph14030204","volume":"14","author":"T Iannaccone","year":"2021","unstructured":"Iannaccone T, Sellitto C, Manzo V, Colucci F, Giudice V, Stefanelli B et al (2021) Pharmacogenetics of carbamazepine and valproate: focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals (Basel) 14(3):204","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"3549_CR28","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1080\/21655979.2022.2036916","volume":"13","author":"W Zhao","year":"2022","unstructured":"Zhao W, Meng H (2022) Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population. Bioengineered 13(3):7709\u20137745","journal-title":"Bioengineered"},{"issue":"8","key":"3549_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-018-2440-6","volume":"74","author":"S Mei","year":"2018","unstructured":"Mei S, Feng W, Zhu L, Li X, Yu Y, Yang W et al (2018) Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model. Eur J Clin Pharmacol 74(8):1029\u20131036","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3549_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154\u2013166","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"3549_CR31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. Aaps j 11(3):558\u2013569","journal-title":"Aaps j"},{"issue":"2","key":"3549_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jppr.1787","volume":"52","author":"P Tippayachai","year":"2022","unstructured":"Tippayachai P, Leelakanok N, Methaneethorn J (2022) Significant predictors for topiramate pharmacokinetics: a systematic review of population pharmacokinetic studies. J Pharm Pract Res 52(2):94\u2013107","journal-title":"J Pharm Pract Res"},{"issue":"1","key":"3549_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/epi.12019","volume":"54","author":"P Manitpisitkul","year":"2013","unstructured":"Manitpisitkul P, Shalayda K, Todd M, Wang SS, Ness S, Ford L (2013) Pharmacokinetics and safety of adjunctive topiramate in infants (1\u201324 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study. Epilepsia 54(1):156\u2013164","journal-title":"Epilepsia"},{"issue":"12","key":"3549_CR34","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157\u20131167","journal-title":"N Engl J Med"},{"issue":"3","key":"3549_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00228-018-2600-8","volume":"75","author":"WW Lin","year":"2019","unstructured":"Lin WW, Li XW, Jiao Z, Zhang J, Rao X, Zeng DY et al (2019) Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur J Clin Pharmacol 75(3):381\u2013392","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3549_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/ern.09.136","volume":"10","author":"C Johannessen Landmark","year":"2010","unstructured":"Johannessen Landmark C, Patsalos PN (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10(1):119\u2013140","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"3549_CR37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","volume":"43","author":"M Bialer","year":"2004","unstructured":"Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE et al (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43(12):763\u2013780","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3549_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","volume":"24","author":"TW May","year":"2002","unstructured":"May TW, Rambeck B, J\u00fcrgens U (2002) Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 24(3):366\u2013374","journal-title":"Ther Drug Monit"},{"issue":"6","key":"3549_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2(6):347\u2013356","journal-title":"Lancet Neurol"},{"issue":"3","key":"3549_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","volume":"38","author":"WE Rosenfeld","year":"1997","unstructured":"Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH et al (1997) Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38(3):324\u2013333","journal-title":"Epilepsia"},{"issue":"11","key":"3549_CR41","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/j.1528-1167.2007.01201.x","volume":"48","author":"C Otoul","year":"2007","unstructured":"Otoul C, De Smedt H, Stockis A (2007) Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 48(11):2111\u20132115","journal-title":"Epilepsia"},{"issue":"7","key":"3549_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","volume":"44","author":"DR Doose","year":"2003","unstructured":"Doose DR, Brodie MJ, Wilson EA, Chadwick D, Oxbury J, Berry DJ et al (2003) Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 44(7):917\u2013922","journal-title":"Epilepsia"},{"key":"3549_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108762","volume":"225","author":"HR Kranzler","year":"2021","unstructured":"Kranzler HR, Hartwell EE, Feinn R, Pond T, Witkiewitz K, Gelernter J et al (2021) Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. Drug Alcohol Depend 225:108762","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"3549_CR44","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/acer.14399","volume":"44","author":"R Lieberman","year":"2020","unstructured":"Lieberman R, Jensen KP, Clinton K, Levine ES, Kranzler HR, Covault J (2020) Molecular correlates of topiramate and GRIK1 rs2832407 genotype in pluripotent stem cell-derived neural cultures. Alcohol Clin Exp Res 44(8):1561\u20131570","journal-title":"Alcohol Clin Exp Res"},{"issue":"3\u20134","key":"3549_CR45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000015558","volume":"88","author":"A Barbon","year":"2000","unstructured":"Barbon A, Barlati S (2000) Genomic organization, proposed alternative splicing mechanisms, and RNA editing structure of GRIK1. Cytogenet Cell Genet 88(3\u20134):236\u2013239","journal-title":"Cytogenet Cell Genet"},{"key":"3549_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.seizure.2017.07.015","volume":"51","author":"C Shen","year":"2017","unstructured":"Shen C, Zhang B, Liu Z, Tang Y, Zhang Y, Wang S et al (2017) Effects of ABCB1, ABCC2, UGT2B7 and HNF4\u03b1 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure 51:102\u2013106","journal-title":"Seizure"},{"issue":"3","key":"3549_CR47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","volume":"3","author":"C Guillemette","year":"2003","unstructured":"Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3(3):136\u2013158","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"3549_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2013.09.002","volume":"141","author":"JC Stingl","year":"2014","unstructured":"Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockm\u00f6ller J (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 141(1):92\u2013116","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3549_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/nu11010090","volume":"11","author":"O Coltell","year":"2019","unstructured":"Coltell O, Asensio EM, Sorl\u00ed JV, Barrag\u00e1n R, Fern\u00e1ndez-Carri\u00f3n R, Portol\u00e9s O et al (2019) Genome-wide association study (GWAS) on bilirubin concentrations in subjects with metabolic syndrome: sex-specific GWAS analysis and gene-diet interactions in a Mediterranean population. Nutrients 11(1):90","journal-title":"Nutrients"},{"issue":"3","key":"3549_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/tpj.2014.65","volume":"15","author":"J Cusato","year":"2015","unstructured":"Cusato J, Allegra S, Massano D, De Francia S, Piga A, D\u2019Avolio A (2015) Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 15(3):263\u2013271","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"3549_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.1109","volume":"105","author":"DK Bhatt","year":"2019","unstructured":"Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H et al (2019) Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin Pharmacol Ther 105(1):131\u2013141","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3549_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/bcp.14985","volume":"88","author":"B Koristkova","year":"2022","unstructured":"Koristkova B, Grundmann M, Brozmanova H, Kacirova I (2022) Was it necessary to change the therapeutic range of topiramate? Br J Clin Pharmacol 88(2):613\u2013618","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03549-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:03:57Z","timestamp":1694750637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3549"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03549-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, and approved by the Ethics Committee of Beijing Children\u2019s Hospital (ID: 2019-k-265).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from legal guardians included in the study. Participants were assured of the confidentiality and anonymity of their personal information and data. Any identifying information was removed or anonymized to ensure privacy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}